SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-17-000212
Filing Date
2017-01-26
Accepted
2017-01-26 08:30:20
Documents
3
Period of Report
2017-01-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K acrs-20170125x8k.htm 8-K 43081
2 EX-99.1 acrs-20170125ex99118fa16.htm EX-99.1 9571
3 GRAPHIC acrs20170125ex99118fa16001.jpg GRAPHIC 759489
  Complete submission text file 0001558370-17-000212.txt   1081116
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37581 | Film No.: 17548117
SIC: 2834 Pharmaceutical Preparations